The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 252, Issue 12, 2014, Pages 1911-1920

  Elshout, Mari ^a   van der Reis, Margriet I ^a   Webers, Carroll A B ^a   Schouten, Jan S A G ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aflibercept; Age related macular degeneration; Bevacizumab; Cost effectiveness; Ranibizumab

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; BLINDNESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CROSS-SECTIONAL STUDY; DRUG COST; DRUG UTILIZATION; ENDOPHTHALMITIS; EVALUATION STUDY; EYE INJURY; FEMALE; FOLLOW UP; HOME CARE; HUMAN; LENS INJURY; LIFE EXPECTANCY; LOW VISION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA HEMORRHAGE; TIME; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; MIDDLE AGED; MONTE CARLO METHOD; PHYSIOLOGY; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; MODELS, ECONOMIC; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84920903579     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-014-2641-3     Document Type: Article

References (19)

1. Klaver CC, Wolfs RC, Vingerling JR, Hofman A, de Jong PT (1998) Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 116:653–658
2. Wang JJ, Foran S, Mitchell P (2000) Age-specific prevalence and causes of bilateral and unilateral visual impairment in older Australians: the Blue Mountains Eye Study. Clin Exp Ophthalmol 28:268–273
3. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119:1399–1411
4. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388–1398. doi:10.1016/j.ophtha.2012.03.053
5. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537–2548. doi:10.1016/j.ophtha.2012.09.006
6. Busbee BG, Brown MM, Brown GC, Sharma S (2003) CME review: a cost-utility analysis of laser photocoagulation for extrafoveal choroidal neovascularization. Retina 23:279–287, quiz 443–274
7. Fletcher EC, Lade RJ, Adewoyin T, Chong NV (2008) Computerized model of cost-utility analysis for treatment of age-related macular degeneration. Ophthalmology 115:2192–2198
8. Larouche K, Rochon S (2004) Evaluation of photodynamic therapy for the treatment of exudative age-related macular degeneration (ARMD) with subfoveal neovascularization (Structured abstract). Montreal: Agence d’Evaluation des Technologies et des Modes d’Intervention en Sante (AETMIS): 101
9. Brown MM, Brown GC, Brown HC, Peet J (2008) A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology 115(1039–1045):e1035
10. Brown GC (1999) Vision and quality-of-life. Trans Am Ophthalmol Soc 97:473–511
11. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH (2004) Handleiding voor kostenonderzoek. Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. CVZ, Diemen
12. Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I (2008) The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 115:116–126
13. (2010) Generatie-overlevingstafels; geslacht en leeftijd (peilmoment 2008). Gewijzigd op 15 februari 2010. Centraal Bureau voor de Statistiek: [http://statline.cbs.nl/StatWeb/dome/default.aspx] Accessed: 7-6-2010
14. Roijen LH-v, Tan SS, Bouwmans CAM (2010) Handleiding voor Kostenonderzoek - Methoden en standaard kostprijzen voor economische evaluaties in de gezonheidszorg. College voor Zorgverzekeringen, Diemen
15. Statistics Netherlands. Consumer prices; price index 2006 = 100. http://statline.cbs.nl
16. PPPs and Exchange rates. Organisation for Economic Co-operation and Development. http://stats.oecd.org/Index.aspx?datasetcode=SNA_TABLE4 [accessed 9 February 2014]
17. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431
18. Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W (2010) Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ 340:c2459
19. Van der Reis MI, La Heij EC, Jong-Hesse YD, Ringens PJ, Hendrikse F, Schouten JS (2011) A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 31:1449–69. doi:10.1097/IAE.0b013e3182278ab4